High expression of P4HA3 in obesity: a potential therapeutic target for type 2 diabetes

Area of Science:

• Biochemistry
• Metabolic Diseases
• Cell Biology

Background:

• Obesity and type 2 diabetes mellitus (T2DM) are complex metabolic disorders.
• The role of specific enzymes, like prolyl 4-hydroxylase subunit alpha 3 (P4HA3), in these conditions requires further elucidation.

Purpose of the Study:

• To investigate the expression of P4HA3 in adipocytes and adipose tissue.
• To determine the functional impact of P4HA3 on adipocyte differentiation and insulin resistance.
• To explore the potential of P4HA3 as a therapeutic target for obesity and T2DM.

Main Methods:

• Assessed P4HA3 expression in human adipose tissue from obesity and T2DM patients.
• Utilized in vitro (3T3-L1 cells) and in vivo (C57BL/6J db/db mice) models to study P4HA3 function.
• Employed gene silencing techniques (knockdown) to inhibit P4HA3 activity.
• Analyzed key metabolic parameters including body weight, blood glucose, triglycerides, and insulin signaling pathways.

Main Results:

• P4HA3 expression was significantly elevated in the adipose tissue of obesity and T2DM patients.
• P4HA3 knockdown in 3T3-L1 cells inhibited adipocyte differentiation and improved insulin resistance.
• In diet-induced obese mice, P4HA3 silencing reduced body weight, adipose tissue mass, fasting blood glucose, and triglyceride levels.
• P4HA3 knockdown promoted the IRS-1/PI3K/Akt/FoxO1 signaling pathway, improving hepatic glucose metabolism and reducing steatosis.

Conclusions:

• Dysregulation of P4HA3 is implicated in the pathogenesis of obesity and T2DM.
• Targeting P4HA3 may offer a novel therapeutic strategy for managing metabolic disorders.
• P4HA3 influences adipogenesis, insulin sensitivity, and hepatic glucose homeostasis.